Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Feb;43(1):134-139.
doi: 10.19852/j.cnki.jtcm.2023.01.012.

Effectiveness and safety of Jinshuibao capsules in treatment of residual cardiopulmonary symptoms in convalescent patients of coronavirus disease 2019: a pilot randomized, double-blind, placebo-controlled clinical trial

Zhang Yuehong  1 , Dong Dandan  2 , Yan Youqin  2 , Zhang Hao  3   4   5 , Wang Guangli  2 , Zhou Wei  2 , L I Wei  2 , Qiu Li  2 , L I Tingming  2 , Liu Quan  3   4   5 , Xia Ping  6   7 , Mao Lina  6   7 , Yang Danlin  2 , Yang Lu  3   4   5 , Lian Fengmei  1 , Tong Xiaolin  1 , B A Yuanming  3   4   5
Affiliations
Randomized Controlled Trial

Effectiveness and safety of Jinshuibao capsules in treatment of residual cardiopulmonary symptoms in convalescent patients of coronavirus disease 2019: a pilot randomized, double-blind, placebo-controlled clinical trial

Zhang Yuehong et al. J Tradit Chin Med. 2023 Feb.

Abstract

OBJECTIVE:: To evaluate the effectiveness and safety of Jinshuibao capsules (金水宝胶囊), a Traditional Chinese Medicine (TCM), in the treatment of residual cardiopulmonary symptoms in convalescent corona virus disease 2019 (COVID-19) patients.

METHODS:: A total of 200 participants with COVID-19 in convalescence phase were randomly assigned into two groups at a 1:1 ratio in this multicenter randomized, double-blind, placebo-controlled trial. One group received Jinshuibao capsules, and the other received placebo. The patients were followed up at one and two weeks of treatment. Five symptoms (dry cough, shortness of breath, sweating, chest tightness and palpitation) improvement rates and full recovery rates were compared.

RESULTS:: All baseline characteristics were comparable between the two groups. After two weeks of treatment, symptom improvement rates for dry cough (74.00% vs 50.00%, P = 0.015), shortness of breath (78.95% vs 46.15%, P < 0.001), sweating (80.00% vs 57.75%, P = 0.004), chest tightness (87.06% vs 60.47%, P < 0.001) and palpitation (82.50% vs 64.56%, P = 0.010) were significantly higher in the Jinshuibao group compared with the control group. Meanwhile, Jinshuibao capsules treatment also displayed more satisfactory full recovery rates of all five symptoms (dry cough 58.00% vs 19.57%, shortness of breath 18.95% vs 7.69%, sweating 36.00% vs 19.72%, chest tightness 32.94% vs 13.95%, and palpitation 48.75% vs 29.11%) in participants with COVID-19 in convalescence phase compared with the control group (P < 0.05). No severe adverse events were reported in either group.

CONCLUSIONS:: Jinshuibao capsules have the potential to improve residual cardiopulmonary symptoms in convalescent COVID-19 patients, with few adverse events.

Keywords: COVID-19; Jinshuibao capsules; convalescence; randomized controlled trial; signs and symptoms.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Flow diagram of participant screening, randomization, and treatment
PPS: per-protocol set.
See this image and copyright information in PMC

References

    1. Liu HQ, Yuan B, An YW, et al.. Clinical characteristics and follow-up analysis of 324 discharged COVID-19 patients in Shenzhen during the recovery period. Int J Med Sci 2021; 18: 347-55. - PMC - PubMed
    1. Sonnweber T, Sahanic S, Pizzini A, et al.. Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial. Eur Respir J 2021; 57: 2003481. - PMC - PubMed
    1. Tian FN, Ke J, . Chen J, et al. Investigation and analysis of Traditional Chinese Medicine symptoms during recovery period in patients with COVID-19. Yi Yao Dao Bao 2020; 39: 637-9.
    1. Fricke-Galindo I, . Falfán-Valencia R. Pharmacogenetics approach for the improvement of COVID-19 treatment. Viruses 2021; 13: 413. - PMC - PubMed
    1. Kheirabadi D, Haddad F, Mousavi-Roknabadi RS, Rezaeisadrabadi M, Dehghan H, Fazlzadeh A.A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic. J Med Virol 2021; 93: 2705-21. - PMC - PubMed

Publication types